Klopidogrel Pharmas

Clopidogrel, the active ingredient in Klopidogrel Pharmas, is a P2Y12 receptor antagonist presented as a tablet for oral use. It helps prevent thrombotic events in patients with recent myocardial infarction, prior ischemic stroke or transient ischemic attack, and established peripheral arterial disease.

GNH USA supplies Klopidogrel Pharmas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clopidogrel acts on platelet aggregation pathways to reduce the risk of arterial thrombotic events. It is indicated for: - Recent myocardial infarction: lowers the chance of cardiovascular death, recurrent MI or stroke. - Ischemic stroke or transient ischemic attack: reduces the risk of a subsequent stroke. - Peripheral arterial disease: decreases major adverse limb events and cardiovascular complications.

Clopidogrel may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Bleeding gums - Easy bruising - Nausea - Diarrhea - Headache - Skin rash

Serious or Rare Side Effects: - Intracranial or gastrointestinal hemorrhage - Severe thrombocytopenia - Anaphylactic or severe allergic reactions - Liver enzyme elevation - Thrombotic thrombocytopenic purpura (TTP)

Before prescribing clopidogrel, clinicians should evaluate individual risk factors and monitor patients closely. - Assess bleeding risk: review history of hemorrhage or surgery. - Monitor platelet function: consider laboratory testing if unexpected bleeding occurs. - Avoid in active pathological bleeding: discontinue if severe bleeding develops. - Caution with hepatic impairment: dose adjustment may be required. - Review concomitant drugs: anticoagulants, NSAIDs and other antiplatelets increase bleeding risk. - Store at room temperature: keep in the original container, protect from moisture and light.

Clopidogrel interacts with several drug classes; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Warfarin: markedly increased bleeding risk. - Other antiplatelet agents (aspirin, ticagrelor): additive hemorrhagic effect. - CYP2C19 inhibitors (omeprazole, fluconazole): may raise clopidogrel plasma levels. - NSAIDs (ibuprofen, naproxen): heightened gastrointestinal bleeding. - Heparin or low‑molecular‑weight heparin: synergistic anticoagulation.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce antiplatelet efficacy. - SSRIs (fluoxetine, sertraline): modest increase in bleeding tendency. - ACE inhibitors: monitor for hypotension when combined with antiplatelet therapy.